NeuroscienceOctober 5, 2025Jannik Nicklas Eliasen, Amir Rezagholizadeh, Helene Påbøl Jacobsen et al.1 citation
Depression and substance use disorder affect millions world-wide, and risk factors include sex. Conventional pharmacotherapies show at best a 50 % success rate. Psychedelics exhibit both anti-addictive and anti-depressive properties. One of these, ibogaine, a root bark sourced alkaloid, interacts with receptors implicated in anti-depressive and anti-addictive effects with affinities in the...
Psychedelics show promise in treating psychiatric disorders. Therapeutic effects appear to involve activation of the 5-Hydroxytryptamine 2A receptor (5-HT2AR), a G protein-coupled receptor (GPCR). Several SNPs of the 5-HT2AR naturally occur, which are associated with differences in receptor function and altered responsiveness to treatments. New compounds suspected to act at the 5-HT2AR are...
A compromised γ-aminobutyric acid (GABA)ergic system is hypothesized to be part of the underlying pathophysiology of schizophrenia. N-methyl-D-aspartate (NMDA) receptor hypofunction during neurodevelopment is proposed to disrupt maturation of interneurons causing an impaired GABAergic transmission in adulthood. The present study examines prefrontal GABAergic transmission in adult rats...